Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 26, 2023 07:00 ET | Source: Talaris Therapeutics, Inc.

Talaris Therapeutics Announces Leadership Transition

BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and...
February 16, 2023 07:00 ET | Source: Talaris Therapeutics, Inc.

Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan

BOSTON and LOUISVILLE, Ky., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced that it has completed a review of its business and program prospects. Based...
November 22, 2022 07:00 ET | Source: Talaris Therapeutics, Inc.

Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference

BOSTON and LOUISVILLE, Ky., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
November 10, 2022 07:00 ET | Source: Talaris Therapeutics, Inc.

Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update

Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients Two presentations at the 2022 American Society of Nephrology (ASN) Annual...
November 07, 2022 07:00 ET | Source: Talaris Therapeutics, Inc.

Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance

BOSTON and LOUISVILLE, Ky., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
October 20, 2022 07:00 ET | Source: Talaris Therapeutics, Inc.

Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial

BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
October 17, 2022 07:00 ET | Source: Talaris Therapeutics, Inc.

Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting

BOSTON and LOUISVILLE, Ky., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
October 04, 2022 07:00 ET | Source: Talaris Therapeutics, Inc.

Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa

BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
September 21, 2022 07:00 ET | Source: Talaris Therapeutics, Inc.

Talaris Therapeutics to Present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event

BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
September 06, 2022 07:00 ET | Source: Talaris Therapeutics, Inc.

Talaris Therapeutics to Participate in Two Upcoming Investor Conferences

BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...